Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE® (trofinetide)
Pipeline
Pipeline
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Hypoxic-ischemic encephalopathy
Prader-Willi Syndrome
Compassionate Use
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
Jul 11, 2005
Walter Reed NNZ-2566 Contract Expanded
Jun 06, 2005
FDA advances Neuren to Phase
May 30, 2005
Results of Annual General Meeting
May 30, 2005
AGM - CEO Presentation
May 20, 2005
Appendix 3B
Apr 29, 2005
Commitments Test Entity - First Quarter Report
Apr 22, 2005
Annual Report 2004 & Notice of AGM
Mar 31, 2005
Annual Report 2004
Mar 17, 2005
Neuren CEO Update March 2005
Mar 15, 2005
Walter Reed Collaboration
Previous
1
2
3
4
5
6
Next
